Director, Corporate & Securities Counsel

About Avalyn: Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has demonstrated encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA-IPF, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn . Position Overview: The Director, Corporate & Securities Counsel will lead the legal side of being a public company — SEC reporting, securities compliance, corporate governance, and everything that comes with operating under the Nasdaq and SEC rulebooks — while also serving as a trusted, senior legal advisor to the broader business. As a recently-IPO'd, small-cap biotech, we need an experienced attorney who can operate with minimal oversight: independently running the reporting and disclosure process, advising senior management and the Board directly, exercising sound judgment on when to escalate, and building the scalable systems and controls this function will need as Avalyn matures as a public company. This is a senior, high-visibility role reporting directly to the General Counsel/Head of Business Development, with regular direct exposure to the CEO, CFO, Board, and Audit Committee. As the second attorney at Avalyn, this person will operate as a true senior individual contributor owning significant scope independently rather than managing a team. Beyond securities and governance work, the role has ownership across the full range of legal functions in a public biotech — commercial contracting, compliance, intellectual property, data privacy, employment matters, and business development — and will help shape how the Legal function's processes, systems, and outside counsel relationships are built as the company scales. Key Responsibilities: SEC Reporting & Disclosure Lead the legal review of periodic reports (Forms 10-K, 10-Q, 8-K) for securities law compliance and disclosure adequacy; Finance owns drafting, financial content, and filing mechanics Draft and review risk factors, legal proceedings disclosures, and other legally-sensitive content; partner with Finance on the broader disclosure controls and procedures process Lead the annual proxy statement (DEF 14A) and annual meeting process, including drafting, SEC review, and timeline management Section 16 & Insider Trading Own legal compliance for Section 16, including review and filing of Forms 3, 4, and 5; partner with Finance/Stock Administration, who support with transaction data and recordkeeping Administer the insider trading policy, including pre-clearance procedures, blackout periods, and 10b5-1 trading plans Monitor and advise on Reg FD considerations in coordination with IR Equity & Stock Administration Provide legal and securities law review of the equity incentive plan and its Form S-8 regis…